Trial Profile
A Phase 1, Open-label, Dose Escalation Study To Evaluate Safety, Pharmacokinetics And Pharmacodynamics Of Combined Oral C-met/Alk Inhibitor (Pf-02341066) And Pan-her Inhibitor (Pf-00299804) In Patients With Advanced Non-small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Crizotinib (Primary) ; Dacomitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Pfizer
- 17 Feb 2016 Results published in the Journal of Thoracic Oncology
- 06 Mar 2014 According to the ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
- 06 Mar 2014 According to the ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.